Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s TROP2 ADC Gets Breakthrough Therapy Tag in US
December 10, 2024
- Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
- Santen Eye Care to Roll Out Alesion AGs on Jan. 20
December 9, 2024
- Japan Ethical Drug Sales Up 6.3% in October: Crecon
December 9, 2024
- LEO Pharma Japan Set to Follow Global Growth as Stand-Alone Sales Force Matures
December 9, 2024
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Mitsubishi, Dewpoint Join Hands on ALS Drug Targeting TDP-43
December 6, 2024
- Nxera Starts PIII Insomnia Drug Trial in South Korea; Data Due Out in 1H 2026
December 6, 2024
- Alzheimer’s Med Leqembi Approved in Mexico
December 6, 2024
- Keytruda Tops Drug Sales Ranking for 14th Month in November: Encise
December 6, 2024
- Takeda Bags Rights to Keros Therapeutics’ Elritercept
December 5, 2024
- Medipal, JCR Kick Off Japan PI/II of MPS IIIB Therapy
December 4, 2024
- Ono Teams Up with Canada’s Congruence in Cancer Drug Discovery
December 4, 2024
- Australia Accepts Shionogi’s NDA for Antibiotic Cefiderocol
December 4, 2024
- Forxiga Crowned in HP Market Promotion Ranking in October: Intage
December 4, 2024
- GE HealthCare to Fully Acquire Nihon Medi-Physics Next Year
December 3, 2024
- LEO Pharma’s Adtralza Pen Version Now Available in Japan
December 3, 2024
- Nichi-Iko Curbs Supply of Hirudoid Generic in Elective Care Fallout
December 3, 2024
- Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market
December 2, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…